Diagnostic Symposium

Co-targeting Driver Pathways: Efficacy and Safety on Tuesday, May 10th

Join NeoGenomics for our upcoming Diagnostic Symposium on Tuesday, May 10, 9 to 10 a.m. PT. Learn from industry-leading thought leaders during this one-hour session on "Co-targeting Driver Pathways: Efficacy and Safety.

The featured speaker of this Diagnostic Symposium is Dr. Razelle Kurzrock, Oncologist and Chief Medical Officer, WIN Consortium. It will be hosted by Derek Lyle, MD, NeoGenomics’ Chief Medical Officer of Clinical Services, and Fernando J. López-Díaz, PhD, NeoGenomics’ Principal Scientist, Research and Development.

Learning objectives for the attendees of this virtual symposium include how to target pathways in cancer when there is more than one driver, efficacy of customized combinations, and how to safely combine drugs based on the IPREDICT (Nature Medicine 2019) experience.

Watch the recording, here


Learn more about the speakers

Razelle Kurzrock, MD

Oncologist and CMO @WIN Consortium

Razelle Kurzrock, MD is a world-renowned physician-scientist leader in Precision Medicine as well as the development of novel therapeutics in the field of oncology. She is recognized for founding, developing and chairing one of the largest Phase 1 clinical trial departments globally while at UT MD Anderson Cancer Center and also one of the pioneer trialists of the WINTHER precision medicine trial focusing, for the first time, on transcriptomics in addition to genomics. This trial was the signature study of the WIN international consortium (Nature Medicine). At UC San Diego Health, she led the Center for Personalized Cancer Therapy, the Experimental Therapeutics program, and she founded a Rare Tumor Clinic focused on precision medicine. The signature study of the center was the IPREDICT study (Nature Medicine, 2019) that gave, for the first time, individualized matched combination therapies to patients with lethal malignancies, resulting in improved outcomes.

Derek Lyle, MD

Chief Medical Officer of Clinical Services @NeoGenomics

Dr. Lyle joined NeoGenomics in 2018. Before joining NeoGenomics, Dr. Lyle worked at Genoptix Medical Laboratory for 9 years, where he initially served as Director of Hematopathology and, later, as Medical Director and Chief Medical Officer. Prior to joining Genoptix, Dr. Lyle worked as a surgical pathologist in Palm Springs, CA. Dr. Lyle completed combined Anatomic Pathology and Clinical Pathology residency training at Cedars-Sinai Medical Center in Los Angeles, CA, where he served as Chief Resident, and a Hematopathology fellowship at City of Hope National Medical Center. He is board-certified in Anatomic Pathology, Clinical Pathology, and Hematopathology.

Fernando López-Díaz, PhD

Principal Scientist, Research & Development @NeoGenomics

Dr López-Díaz’s background is on molecular biology, from genomics and cancer pathways to immuno-oncology. He obtained his BS/MS in Clinical Biochemistry and his PhD in Biochemistry in Argentina and completed a postdoctoral training in cancer molecular biology at the Salk Institute with Dr. Beverly Emerson. He has 12+ years of academic career including joint appointments as Staff Scientist at the Salk Institute, UCSD Visiting Scientist and Adjunct Faculty at University Francisco de Vitoria in Spain. He trained scientists and students and led multi-disciplinary projects by Salk, UCSC Genome Technology Center and UCSF scientists making seminal discoveries in cancer progression, drug resistance and single-cell genomics. He authored high profile publications widely cited in top journals including The Lancet, Cancer Cell, Nature Reviews Cancer, etc. He co-founded a Precision Oncology network in Argentina, developed and lectured worldwide at Precision Oncology symposiums.


The content in the blogs herein relate to the opinions and views expressed by the individual blog author(s) and contributors and are not necessarily the viewpoints held by NeoGenomics Inc., or any of its affiliates or entities.

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients